Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.

Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, Schultze-Mosgau A

Human reproduction (Oxford, England)15 Feb 2007Cited by 77 (Europe PMC)

PMID17303632DOI10.1093/humrep/dem006PepBankPUB-17303632

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In OHSS-risk patients, triptorelin triggering followed by cryopreservation and frozen embryo transfer yielded a cumulative ongoing pregnancy rate of 36.8%.
In plain wordsIn patients at risk of OHSS, the triptorelin and frozen embryo transfer regimen yielded a cumulative ongoing pregnancy rate of 36.8%.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableCumulative ongoing pregnancy rate
Study
n = 19
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Cumulative ongoing pregnancy
36.8%
per patient
95% confidence interval
19.1 to 59%
per patient
Source sentences
Summary
The cumulative ongoing pregnancy rate was 36.8% (95% confidence interval: 19.1-59.0%).
3 context sentences(design, population, supporting numbers)
Summary · context
Of the 20 patients triggered with GnRH agonist, 19 patients underwent 24 FT-ETs in the observational period.
Summary · context
after ovarian stimulation and concomitant GnRH-antagonist administration had final oocyte maturation triggered with 0.2 mg triptorelin s.c.
Summary · context
All two pronucleate (2 PN) oocytes were cryopreserved by vitrification, and frozen-thawed ETs (FT-ETs) were performed in an artificial cycle.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1730363201
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In OHSS-risk patients, ongoing pregnancy after the first frozen embryo transfer following triptorelin triggering was 31.6%.
In plain wordsIn patients at risk of OHSS, ongoing pregnancy after the first frozen embryo transfer following triptorelin triggering was 31.6%.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableOngoing pregnancy after first frozen embryo transfer
Study
n = 19
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Ongoing pregnancy
31.6%
first frozen embryo transfer
Confidence interval for ongoing pregnancy rate per first FT-ET
15.4 to 54%
first frozen embryo transfer
Source sentences
Summary
The ongoing pregnancy rate per first FT-ET was 31.6% (15.4-54.0%).
3 context sentences(design, population, supporting numbers)
Summary · context
Of the 20 patients triggered with GnRH agonist, 19 patients underwent 24 FT-ETs in the observational period.
Summary · context
after ovarian stimulation and concomitant GnRH-antagonist administration had final oocyte maturation triggered with 0.2 mg triptorelin s.c.
Summary · context
All two pronucleate (2 PN) oocytes were cryopreserved by vitrification, and frozen-thawed ETs (FT-ETs) were performed in an artificial cycle.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1730363202
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studySafety outcome
No moderate or severe OHSS occurred with the triptorelin-triggering and oocyte-cryopreservation regimen in patients at increased OHSS risk.
In plain wordsNo moderate or severe OHSS occurred with the triptorelin and oocyte-freezing regimen in patients at increased risk.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableModerate or severe OHSS
Study
n = 20
Analysis
Secondary
Outcome group
Adverse events · Reproductive and sexual health
Source sentences
Summary
No cases of moderate or severe OHSS were observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Of the 20 patients triggered with GnRH agonist, 19 patients underwent 24 FT-ETs in the observational period.
Summary · context
after ovarian stimulation and concomitant GnRH-antagonist administration had final oocyte maturation triggered with 0.2 mg triptorelin s.c.
Summary · context
All two pronucleate (2 PN) oocytes were cryopreserved by vitrification, and frozen-thawed ETs (FT-ETs) were performed in an artificial cycle.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1730363203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.